The Faculty of Engineering and School of Pharmacy, at the University of Nottingham, are delighted to announce the receipt of an MRC Confidence in Concepts grant.

The University of Nottingham is a Medilink EM Patron and works with Medilink EM to drive life science growth across the East Midlands. The University of Nottingham will be working alongside fellow Medilink EM Patron Quotient Sciences, alongside Added Scientific and AstraZeneca. The grant will translate towards clinical applications some of the advances made at Nottingham in the 3D printing of pharmaceutical dosage forms.

The 12-month project aims to demonstrate the ability to manufacture personalised dosage forms in a regulated industrial environment focused on medicines development and clinical trials.

Professors Ricky Wildman and Clive Roberts, who the lead the project, commented: “This project is an exciting opportunity to work with leading industrial partners in clinical trials, additive manufacturing and pharmaceuticals, and is an important step for us in exploring the potential of 3D printing for the improvement of human health and wellbeing through more personalised medicines.”

”The scope for 3D printing in the pharmaceutical industry is significant, with potential applications including the rapid development of prototype dosage forms and the ability to personalise drug products to individual patient needs, for example in rare, orphan and paediatric diseases,” said Dr Peter Scholes, Chief Scientific Officer at Quotient Sciences. “We are excited to be part of this collaborative program which will look to translate the research performed at the University of Nottingham into an industrial manufacturing setting”.

Dr Johanna Laru, Associate Director, Pharmaceutical Sciences, R&D at AstraZeneca commented: “We know the best science doesn’t happen in isolation. This grant builds on our existing collaboration with the University of Nottingham, Quotient Sciences and Added Scientific, and we look forward to working together to further assess the potential of 3D printing in the medicines development.”

Added Scientific are very excited to be part of this work after our involvement in an earlier collaborative project looking at the feasibility of printing pills. The opportunity to observe, learn and benefit from the first human trials of this technology will be invaluable to the company and its engineers and scientists.

For more information on Medilink EM Patronage, click here

Latest Opportunities

Single manufacturer & supplier required for human skin patch: Formulation, manufacture, and packing

Opportunity Company:  Nottingham-based MedTech company Requires: Seeking a single manufacturer and supplier for the formulation,…

Medilink Midlands Job Vacancy - Innovation Adviser

About the job Innovation Adviser – Midlands region – Full time salary £40-45K – Home…

Global Business Innovation Programme: Health & Medical Technologies - Singapore

Innovate UK is inviting ambitious innovative companies to participate in its Global Business Innovation Programme…

Latest News

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep – Helping Gamers…

Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters…

EU MDR/IVDR Revision: A Gateway for Chinese Innovators Entering UK and EU Markets via EFEC

In a significant move for the global medtech landscape, the European Commission has initiated a…